

**PRESS RELEASE**

**Ad hoc announcement pursuant to article 53 LR**

## **LEPU Medical Technology(Beijing) Announces Results for the First Quarter of 2024**

Beijing, China, April 20, 2024- LEPU Medical Technology(Beijing) Co.,Ltd.(the “Company”) today announced its performance for the three months ended March 31, 2024:

- During the reporting period, the Company's operating income was RMB 1922.0288 million with a year-on-year decrease of 21.14% and a month-to-month increase of 11.70% compared with 2323Q4. The main reason for the year-on-year decrease in income was that some emergency products were still sold last year, and they were concentrated in Q1. The income of each business sector is as follows:
- The operating income of medical devices reached RMB 885.6198 million, with a year-on-year decrease of 18.69% and a month-to-month increase of 9.22%. Wherein, the innovative product portfolio of cardiovascular intervention achieved a year-on-year increase of 19.92%. The income of important sub-sectors in medical device business is as follows:
- Coronary intervention business: The operating income reached RMB 438.0181 million, with a year-on-year increase of 5.80% and a month-to-month increase of 22.17%.
- Structural heart disease business: The operating income reached RMB 112.7253 million, with a year-on-year increase of 66.77% and a month-to-month increase of 45.45%.
- Surgical anesthesia business: The operating income reached RMB 136.6886 million, with a year-on-year increase of 10.24% and basically unchanged month-to-month increase.

- In vitro diagnosis business: The operating income reached RMB 110.3790 million, with a year-on-year decrease of 69.53%, caused by high base due to sales of emergency products in the same period of the last year, and with a month-to-month increase of 6.30%.
- The operating income of pharmaceutical reached RMB 792.9157 million, with a year-on-year decrease of 15.69% and a month-to-month increase of 26.35%. The operating income of active pharmaceutical ingredients reached RMB 102.4139 million, with a year-on-year increase of 19.15%; The operating income of preparations reached RMB 690.5018 million, with a year-on-year decrease of 19.19%;
- The operating income of medical service and health management reached RMB 243.4933 million, with a year-on-year decrease of 40.26%, caused by high base due to emergency products in the same period of the last year, and with a month-to-month decrease of 13.73%. Wherein, the operating income of Hefei Cardiovascular Hospital reached RMB 38.2155 million, with a year-on-year increase of 13.58%.
- During the reporting period, the Company achieved a net profit of RMB 492.7605 million, with a year-on-year decrease of 20.31%; Net profit attributable to shareholders of the Company was RMB 481.8711 million, with a year-on-year decrease of 19.27%; The net profit attributable to shareholders of listed companies after non-recurring profits and losses were deducted was RMB 456.4338 million, with a year-on-year decrease of 18.85%, and the total non-recurring profits and losses was RMB 25.4373 million, mainly due to the decrease in government subsidies received.

### **Financial Results(unaudited)**

	Current reporting period	Same period of last year	The increase/decrease of the report period from the same period of the previous year (%)
Operating income (RMB)	1, 922, 028, 839. 15	2, 437, 202, 386. 92	-21. 14%
Net profits attributable to	481, 871, 134. 58	596, 924, 222. 49	-19. 27%

shareholders of the listed companies (RMB)			
Net profits attributable to shareholders of the listed company after deducting non-recurring profits and losses (RMB)	456,433,815.92	562,429,846.30	-18.85%
Net cash flow from operating activities (RMB)	141,518,257.63	-134,203,435.01	205.45%
Basic earnings per share (RMB/share)	0.2594	0.3205	-19.06%
Diluted earnings per share (RMB/share)	0.2585	0.3177	-18.63%
Weighted average return on net assets	2.98%	3.86%	-0.88%
	End of current reporting period	End of the last year	The increase/decrease of the report period from the end of the previous year (%)
Total assets (RMB)	25,508,525,579.77	25,022,331,486.69	1.94%
Owners' equities attributable to shareholders of the Company (RMB)	16,377,673,701.46	15,976,101,963.31	2.51%

## Full first quarter report

The full first-quarter results report as of and for the three months ended March 31, 2024 is available on our website at <https://en.lepumedical.com/investors/>.

## Contact information

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: [zqb@lepumedical.com](mailto:zqb@lepumedical.com)

## About LEPU

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions Company is one of the earliest companies in the PRC to offer coronary

interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

## **Disclaimers**

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be

accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.